- Home
- AX vs ACAD Comparison
AX vs ACAD Comparison
Compare AX & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AX
- ACAD
- Stock Information
- Founded
- AX 1999
- ACAD 1993
- Country
- AX United States
- ACAD United States
- Employees
- AX N/A
- ACAD N/A
- Industry
- AX Savings Institutions
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- AX Finance
- ACAD Health Care
- Exchange
- AX Nasdaq
- ACAD Nasdaq
- Market Cap
- AX 4.9B
- ACAD 4.3B
- IPO Year
- AX 2005
- ACAD 2004
- Fundamental
- Price
- AX $75.52
- ACAD $20.54
- Analyst Decision
- AX Strong Buy
- ACAD Buy
- Analyst Count
- AX 7
- ACAD 20
- Target Price
- AX $96.57
- ACAD $29.25
- AVG Volume (30 Days)
- AX 351.6K
- ACAD 2.5M
- Earning Date
- AX 10-30-2025
- ACAD 11-05-2025
- Dividend Yield
- AX N/A
- ACAD N/A
- EPS Growth
- AX N/A
- ACAD 615.00
- EPS
- AX 7.43
- ACAD 1.33
- Revenue
- AX $1,203,093,000.00
- ACAD $1,018,885,000.00
- Revenue This Year
- AX $14.04
- ACAD $14.01
- Revenue Next Year
- AX $8.53
- ACAD $11.81
- P/E Ratio
- AX $11.09
- ACAD $16.41
- Revenue Growth
- AX 13.59
- ACAD 14.41
- 52 Week Low
- AX $54.46
- ACAD $13.40
- 52 Week High
- AX $93.84
- ACAD $26.65
- Technical
- Relative Strength Index (RSI)
- AX 29.49
- ACAD 38.00
- Support Level
- AX $79.62
- ACAD $19.69
- Resistance Level
- AX $85.50
- ACAD $21.96
- Average True Range (ATR)
- AX 2.89
- ACAD 0.76
- MACD
- AX -0.68
- ACAD 0.01
- Stochastic Oscillator
- AX 2.86
- ACAD 34.65
About AX Axos Financial Inc.
Axos Financial Inc is a bank holding company that operates through its bank subsidiary, BofI Federal Bank, a nationwide bank that provides financing for single and multifamily residential properties, small to medium-size businesses in certain sectors, and selected specialty finance receivables. Its operating segments are banking business segment and securities business segment. The bank distributed its products through a wide range of retail distribution channels, including only banking brands, affinity groups, and sales teams, among others. The majority of the bank's mortgage exposure is titled toward the state of California, particularly its southern region. Net interest income is a majority of the bank's revenue.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.